Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report

Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report

Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini
Natura:	Articolo
Lingua:	English
Pubblicazione:	Interna Publishing 2017-04-01
Serie:	Acta Medica Indonesiana
Soggetti:	tuberculosis fixed-dose combination recurrent
Accesso online:	http://www.actamedindones.org/index.php/ijim/article/view/327

Documenti analoghi

Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
di: Jacqueline Mui Lan Lai, et al.
Pubblicazione: (2019-01-01)

Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
di: Hui Zhu, et al.
Pubblicazione: (2015-01-01)

Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment
di: Jiun-Ting Wu, et al.
Pubblicazione: (2015-06-01)

In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
di: Vanessa Albertina Agertt, et al.

Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan
di: EVA SARTIKA DASOPANG, et al.
Pubblicazione: (2020-02-01)

Comparison of sputum conversion time in tuberculosis treatment with fix-dose combination drugs and separate drug regimens
di: Soheila Khodakarim, et al.
Pubblicazione: (2020-01-01)

Treatment outcome in smear-positive pulmonary tuberculosis patients treated with a fixed-dose drug combination regimen in comparison with a separate regimen: a randomized clinical trial
di: Seyed Saeed Hashemi Nazari, et al.
Pubblicazione: (2021-01-01)

Experience of Fixed-Dose Combinations of Anti-Tuberculosis Drugs for Preventive Treatment in Children
di: O. D. Baronova, et al.
Pubblicazione: (2023-12-01)

Optimization of Hypertension Treatment using Fixed-Dose Combination of Perindropril/Amlodipine
di: Evan Hindoro, et al.
Pubblicazione: (2015-12-01)

Fixed dosed combinations in the treatment of hypertension
di: Gabriel Hancu, et al.
Pubblicazione: (2020-03-01)

Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
di: A. L. Khokhlov, et al.
Pubblicazione: (2022-05-01)

Assessment of treatment outcomes of daily fixed-dose combination therapy among drug-sensitive pulmonary tuberculosis patients: A prospective study from Bengaluru, India
di: M Sumana, et al.
Pubblicazione: (2024-07-01)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
di: Paweł Kawalec, et al.
Pubblicazione: (2018-08-01)

From combined therapy to fixed-dose combinations
di: I. P. Kolos, et al.
Pubblicazione: (2008-08-01)

A promising choice in hypertension treatment: Fixed-dose combinations
di: Xinhuan Wan, et al.
Pubblicazione: (2014-02-01)

Fixed-dose versus separate drug combinations for antihypertensive treatment: literature review
di: José Luis Calleja Rivero
Pubblicazione: (2016-09-01)

Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar
di: Mohammad H. Al-Shaer, et al.
Pubblicazione: (2018-08-01)

Therapy compliance and fixed-dose combinations in arterial hypertension treatment. Focus on a fixed-dose combination of felodipine and metoprolol
di: S. A. Shalnova, et al.
Pubblicazione: (2009-12-01)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
di: Tarantino N, et al.
Pubblicazione: (2017-02-01)

The Roll-out of Child-friendly Fixed-dose Combination TB Formulations in High-TB-Burden Countries: A Case Study of STEP-TB
di: Lena Faust, et al.
Pubblicazione: (2019-08-01)

Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide
di: A. O. Konradi, et al.
Pubblicazione: (2020-04-01)

Critical Analysis of Cardiovascular and Central Nervous System Fixed Dose Combinations Available in Indian Market
di: Krunal Prajapati, et al.
Pubblicazione: (2016-12-01)

Fixed-dose combinations in the treatment of hypertension to increase adherence
di: T. E. Morozova, et al.
Pubblicazione: (2020-12-01)

A cost-minimization analysis of combination therapy in hypertension: fixed-dose vs extemporary combinations
di: Marco Bellone, et al.
Pubblicazione: (2013-12-01)

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
di: Hayes J, et al.
Pubblicazione: (2016-07-01)

Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men
di: Choi HK, et al.
Pubblicazione: (2016-10-01)

Enhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet
di: Tae Han Yun, et al.
Pubblicazione: (2024-07-01)

The use of capillary electrophoresis in the simultaneous determination of fixed-dose combination drugs for cardiovascular diseases
di: Gabriel Hancu, et al.
Pubblicazione: (2020-09-01)

Regulatory requirements for marketing fixed dose combinations
di: B G Jayasheel
Pubblicazione: (2010-01-01)

Clinical use of a fixed-dose combination of telmisartan and indapamide in hypertension. Expert Council resolution
di: A. O. Konradi, et al.
Pubblicazione: (2025-02-01)

Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia
di: Chia‐Pin Lin, et al.
Pubblicazione: (2024-05-01)

Capillary electrophoresis for the assay of fixed-dose combination tablets of artesunate and amodiaquine
di: Amin N’Cho, et al.
Pubblicazione: (2012-05-01)

Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia
di: Ihm SH, et al.
Pubblicazione: (2019-02-01)

The Adherence to Fixed-Dose Combination Antiretroviral Therapy and Viral Load in HIV Patients
di: Salma Auliannissa, et al.
Pubblicazione: (2020-01-01)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
di: Rogliani P, et al.
Pubblicazione: (2018-10-01)

From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India
di: Archana Bhargava, et al.
Pubblicazione: (2022-01-01)

Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers
di: Oh M, et al.
Pubblicazione: (2017-12-01)

Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR
di: Yu. A. Karpov, et al.
Pubblicazione: (2020-11-01)

The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation
di: Elena A. Pyadushkina, et al.
Pubblicazione: (2021-12-01)

IMPACT OF THE FORM OF MEDICATION ON TREATMENT ADHERENCE IN RESPIRATORY TUBERCULOSIS PATIENTS
di: T. E. Tyulkova, et al.
Pubblicazione: (2018-01-01)